Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Brain-Responsive Neurostimulation for the treatment of adults with epilepsy in tuberous sclerosis complex: A case series. Epilepsia open McDermott, D. S., Mirro, E. A., Fetrow, K., Burdette, D. E., Chen, S., Hopp, J., Masel, T., Johnson, E. A., Elefant, F. M., Le, S., Patra, S. E., Brown, M., Haneef, Z. 2021

Abstract

OBJECTIVE: Tuberous sclerosis complex (TSC) is a genetic disorder primarily characterized by the development of multisystem benign tumors. Epilepsy is the most common neurologic manifestation, affecting 80%-90% of TSC patients. The diffuse structural brain abnormalities and the multifocal nature of epilepsy in TSC pose diagnostic challenges when evaluating patients for epilepsy surgery.METHODS: We retrospectively reviewed the safety experience and efficacy outcomes of five adult TSC patients who were treated with direct brain-responsive neurostimulation (RNS System, NeuroPace, Inc).RESULTS: The average follow-up duration was 20months. All five patients were responders (=50% disabling seizure reduction) at last follow-up. The median reduction in disabling seizures was 58% at 1year and 88% at last follow-up. Three of the five patients experienced some period of seizure freedom ranging from 3months to over 1year.SIGNIFICANCE: In this small case series, we report the first safety experience and efficacy outcomes in patients with TSC-associated drug-resistant focal epilepsy treated with direct brain-responsive neurostimulation.

View details for DOI 10.1002/epi4.12481

View details for PubMedID 34033253